Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 13/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802664 | 0.87 | TAS1R3 (0.42) | STING1 | |
| SCHEMBL803169 | 0.86 | NT5E (0.33) | — | |
| SCHEMBL802593 | 0.83 | PI4KA (0.39) | STING1 | |
| SCHEMBL15478065 | 0.83 | PI4KA (0.39) | STING1 | |
| SCHEMBL802642 | 0.78 | — | — | |
| SCHEMBL802588 | 0.77 | ADORA3 (0.35) | — | |
| SCHEMBL25968862 | 0.77 | TK1 (0.34) | — | |
| SCHEMBL9961281 | 0.74 | STING1 (0.37) | STING1 | |
| SCHEMBL802564 | 0.74 | PRMT6 (0.38) | — | |
| SCHEMBL9964274 | 0.73 | STING1 (0.60) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653254-B2 | Process for producing nucleoside | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071646-A1 | PROCESS FOR PRODUCING NUCLEOSIDE | NUDT1, PNP, HPRT1 | STING1 664/4885PDE3B 1123/4885PDE3A 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.